Clinical Research Directory

Inclusion Criteria: * Diagnosed with uHCC, as confirmed by radiology, histology, or cytology * 18 years of age at the time of Lenvatinib initiation for uHCC * Initiated, within standard clinical practice, 1L Lenvatinib (Cohort A) or initiated 2L Lenvatinib after progression on or discontinuation (due to toxicity) of prior immunotherapy (Cohort B) between 01 Sep 2020 and 30 Sep 2023 * BCLC Stage C disease, or BCLC Stage B disease not amenable to locoregional therapy at initial diagnosis of metastatic uHCC * At least one measurable target lesion at Lenvatinib initiation * ECOG performance status 0 or 1 at Lenvatinib initiation * If deceased, have a reported date of death. Cohort A * Child-Pugh A (score 5 or 6) classification of uHCC at Lenvatinib initiation * Initiated Lenvatinib with US FDA approved starting dose (12 mg once daily for patients weighing ≥60 kg, or 8 mg once daily for patients weighing \<60 kg Cohort B * Patients may have either Child-Pugh A (score 5 or 6) or Child-Pugh B (score 7) classification of uHCC at Lenvatinib initiation Exclusion Criteria: * Vp4 at Lenvatinib initiation * Esophageal or gastric variceal bleeding within 6 months before the index date * Had a prior history of other malignancy that required active treatment; exceptions include non-melanoma skin cancer or in situ cervical cancer that has potentially curative therapy underwent * History of liver transplant Cohort A * Received other 1L systemic therapy or LRT concurrently with Lenvatinib Cohort B * Received other immunotherapy not inclusive of atezolizumab plus bevacizumab or durvalumab plus tremelimumab combination therapies * Received other 2L systemic therapy or LRT concurrently with Lenvatinib